DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE belongs to the group of antiretroviral agents indicated for the treatment of HIV-1 infection in adults and children above 12years weighing at least 40kgs. HIV is a virus that attacks the body's immune system, making it compromised and susceptible to various infections and diseases.
DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE contains 'Dolutegravir, Emtricitabine and Tenofovir alafenamide'. DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE works by interfering with the working of HIV-1 reverse transcriptase enzymes which are necessary for the replication of the virus. Together, DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE helps in treating HIV infection.
Take DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE as prescribed. In some cases, DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE may cause certain side effects such as trouble sleeping, headache, nausea, and tiredness. Most of these side effects do not require medical attention and will resolve gradually over time. However, you are advised to talk to your doctor if these side effects persist.
Consult your doctor if you are pregnant, or planning to get pregnant. Avoid breastfeeding while taking DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE. DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE does not help reduce the risk of getting HIV-1 infection by sexual contact; therefore, it is important to practise safe sex to avoid transmitting HIV to your partner. Avoid alcohol consumption while on treatment with DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE.
HIV-1 infection
DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE is an anti-retroviral drug used in the treatment of HIV-1 infection. DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE works by interfering with the replication of HIV and preventing its further progression. It contains Dolutegravir, Emtricitabine and Tenofovir alafenamide. Dolutegravir works by blocking HIV integrase, which is responsible for integrating viral DNA into the host cell. Thus, it inhibits the integration of the viral component into the human body cells. Emtricitabine works by inhibiting reverse transcriptase, which is responsible for transcribing RNA to DNA. By blocking this action, emtricitabine prevents the proliferation of the virus. Tenofovir alafenamide blocks the enzyme polymerase, thereby preventing aggregation of viral components and terminating the DNA chain, thus effectively nipping viral replication in the bud.
Inform the doctor if you are allergic to any of the components of DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE. Consult your doctor if you are pregnant, or planning to get pregnant before taking DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE. Avoid breastfeeding while on treatment with DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE. Avoid alcohol consumption. It is important to practise safe sex to avoid transmitting HIV to your partner. Inform your doctor if you have liver problems, hepatitis infections, heart or kidney problems. Keep your doctor informed about your health condition and medications to rule out any interactions.
Drug-Drug Interactions: DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE may interact with antiviral/anti-HIV drug (adefovir dipivoxil, atazanavir, bictegravir, lamivudine), anti-Tb drug (rifampicin), antidepressant (St John’s wort), ulcer medicine (sucralfate), antibiotics (azithromycin, clarithromycin, rifabutin), immunosuppressants (cyclosporine), anti-epileptics (phenobarbital or phenytoin), antacids, iron supplements and vitamins.
Drug-Food Interactions: No interactions found.
Drug-Disease Interactions: DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE should be used with caution in patients with a known hypersensitivity disorder, diabetes, hypertension, hepatitis, liver disease, kidney disease and/or heart disease.
It is not recommended to consume alcohol with DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE. Please consult your doctor if you have any concerns.
Please consult your doctor if you are pregnant. Your doctor will prescribe if the benefits are found to outweigh the risks.
Avoid breastfeeding while on treatment with DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE.
DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE may cause dizziness and tiredness. Do not drive if you experience any side effects after using DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE.
Exercise caution before using DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE in case of established liver disease. Please consult your doctor to address any concerns.
Exercise caution before using DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE in case of established kidney disease. Please consult your doctor to address any concerns.
DOLUTEGRAVIR+EMTRICITABINE+TENOFOVIR ALAFENAMIDE is not recommended for use in children under 12 years of age. Please consult your doctor in case of any concerns.
HIV infection: HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system and destroys the white blood cells that help in fighting infection, making the individual susceptible to other infections or illnesses. People with HIV experience flu-like symptoms such as fever, chills, rash, night sweats, muscle aches, tiredness, and sore throat. These symptoms usually last for days to several weeks. HIV spreads through body fluids such as semen, vaginal fluid, and blood. If left untreated, this condition can lead to AIDS (Acquired Immunodeficiency Syndrome). It is a life-long condition, and there is no definite cure for it. However, it can be controlled by treating with antiretroviral drugs.